Obidi, JoyceVilla, CarlosStorch, EmilyWhitaker, BarbeeChada, KinneraWilliams, AlanFowler, StephanieSchilling, Lisa M.Kahn, Michael G.Edlavitch, Stanley A.Purkayastha, SaptarshiHayden, RossBiondich, PaulFalconer, ThomasNatarajan, KarthikReich, ChristianShoaibi, Azadeh2022-10-062022-10-062019-09Obidi, J., Villa, C. H., Storch, E., Whitaker, B. I., Chada, K., Williams, A., ... & Shoaibi, A. (2019, September). Trends in RED Blood CELL Transfusions within the Biologics Effectiveness and Safety (BEST) Initiative Network, 2012-2018. In 2019 Annual Meeting. AABB.https://hdl.handle.net/1805/30234The U.S. FDA Center for Biologics Evaluation and Research (CBER) recently established the Biologics Effectiveness and Safety (BEST) Initiative which is an active surveillance system for all CBER regulated products, including blood components, and which also allows for investigation of patterns in utilization. The 2015 National Blood Collection& Utilization Survey (NBCUS) Report found an overall decrease in the number of units of red blood cells (RBCs) transfused in recent years. The aim of this study is to describe the utilization of RBCs from 2012 through 2018 using electronic health records (EHR) from three data sources participating in the BEST Initiative.enBiologics Effectiveness and Safety (BEST) Initiativered blood cell transfusionselectronic health recordsOther